Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 20%Low 0 · 0%Moderate 4 · 80%High 0 · 0%

Extended‐field radiotherapy vs pelvic radiotherapy

Progression‐free survival

Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.92 [0.69, 1.22]
1 study · 377 participants
Moderate

Extended‐field radiotherapy vs pelvic chemoradiotherapy

Progression‐free survival

Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.52 [0.37, 0.72]
1 study · 389 participants
Moderate

Extended‐field chemoradiotherapy vs pelvic chemoradiotherapy

Progression‐free survival

It is very uncertain whether extended‐field chemoradiotherapy changes progression‐free survival compared with pelvic chemoradiotherapy (very low certainty).

1 finding from 1 review

Extended‐field radiotherapy for locally advanced cervical cancer 2018 · Cochrane Headline outcomes only
HR 0.25 [0.07, 0.87]
1 study · 74 participants
Very low

Intervention not reported

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS WT

The intervention probably leads to lower progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.6 [0.48, 0.75]
6 studies · 1237 participants
Moderate

Intervention not reported

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.13 [0.93, 1.36]
6 studies · 2023 participants
Moderate